With the goal of contributing to the advancement of modern medicine and the fight against infectious diseases, Bio-Med Joint Stock Company—official distributor of Abbott’s Alinity m molecular diagnostic system in Vietnam—joined Abbott as a Gold Sponsor of the 2025 Scientific Conference on the Application of Artificial Intelligence (AI) and Big Data in Clinical Practice for Infectious Diseases. The event took place on May 29, 2025, at the Hospital for Tropical Diseases in Ho Chi Minh City.
Infectious diseases have long posed a persistent threat to human health. Today, they remain among the leading causes of morbidity and mortality worldwide. Looking ahead, we continue to face major global health challenges that demand a comprehensive and systemic approach—where innovation plays a central role.
This year’s conference focused on leveraging the power of Artificial Intelligence and Big Data to address infectious diseases. The development of AI is considered as revolutionary as the advent of the personal computer. It is expected to transform how we work, communicate, learn, and revolutionize the healthcare sector by enhancing diagnostic accuracy, accelerating scientific breakthroughs, and providing reliable medical guidance.
In Vietnam, particularly at the Hospital for Tropical Diseases—the country’s oldest infectious disease hospital and a key player in epidemic prevention in Ho Chi Minh City and the southern region—the application of AI and Big Data has been advancing rapidly. The conference featured in-depth presentations on:
-
Medical innovation and the perpetual challenges of infectious diseases
-
Applications of AI and Big Data in infectious disease management at the hospital, including outbreak prediction and warning systems, diagnostics, treatment, hospital operations, and scientific research
-
Use of electronic health data to improve quality of care in Intensive Care Units (ICUs), enabling the identification of priority health issues, evaluating interventions, and enhancing treatment outcomes
-
AI-assisted dengue fever care, including research on the D-SCAPE device, which uses photoplethysmography (PPG) and AI to predict and classify dengue shock syndrome
-
AI-based severity prediction models for tetanus, evaluating real-time feasibility for clinical tasks
-
AI-integrated ultrasound for muscle wasting monitoring in tetanus patients, applying AI to improve the reliability and efficiency of RFCSA (rectus femoris cross-sectional area) measurements at the bedside
AI and Big Data applications in infectious disease include early outbreak prediction, rapid and accurate diagnostics (image and lab data analysis, genetic data), personalized treatment and patient management, drug and therapy development, and hospital resource optimization. Despite challenges—such as data quality, IT infrastructure, skilled personnel, and legal frameworks—solutions like data standardization, cloud computing, interdisciplinary training, and clear regulatory policies are being actively implemented.
As Abbott’s partner and distributor of cutting-edge diagnostic systems like Alinity m, Bio-Med is committed to bringing the latest technologies to improve Vietnam’s diagnostic and treatment capabilities. Our participation in this conference reaffirms Bio-Med’s dedication to supporting Vietnam’s healthcare system in adopting scientific and technological advancements—particularly AI and Big Data—to meet pressing healthcare challenges, and to build a smarter, safer, and healthier future.
At Bio-Med, we believe that close collaboration between institutions is the key to sustainable success in healthcare.
